In addition, NTRK mutant NSCLC patients exhibited increased expression of cytolytic activity markers (GZMA, PRF1), immunological checkpoints (CD274), and chemokines (CXCL9, CXCL10). Here, CXCL10 is linked to non-small cell lung carcinoma.